Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Over the last 12 months, insiders at Eli Lilly and Company have bought $0 and sold $2.35B worth of Eli Lilly and Company stock.
On average, over the past 5 years, insiders at Eli Lilly and Company have bought $478.61M and sold $5.52B worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 29,992,668 shares for transaction amount of $374.91M was made by Kearny Acquisition Corp (director) on 2022‑11‑30.
2024-11-08 | Sale | SVP, Finance, & CAO | 900 <0.0001% | $803.38 | $723,042 | -5.21% | ||
2024-09-03 | Sale | 10 percent owner | 24,084 0.0026% | $966.69 | $23.28M | -6.08% | ||
2024-08-27 | Sale | 10 percent owner | 24,552 0.0026% | $968.46 | $23.78M | -5.42% | ||
2024-08-26 | Sale | SVP, Finance, & CAO | 750 <0.0001% | $950.00 | $712,500 | -4.99% | ||
2024-08-22 | Sale | 10 percent owner | 3,196 0.0003% | $966.33 | $3.09M | -5.23% | ||
2024-07-10 | Sale | 10 percent owner | 210,000 0.023% | $939.82 | $197.36M | 0.00% | ||
2024-07-08 | Sale | 10 percent owner | 93,593 0.01% | $918.64 | $85.98M | 0.00% | ||
2024-07-05 | Sale | 10 percent owner | 52,369 0.0056% | $915.18 | $47.93M | 0.00% | ||
2024-07-03 | Sale | 10 percent owner | 8,848 0.0009% | $915.31 | $8.1M | 0.00% | ||
2024-07-01 | Sale | 10 percent owner | 58,749 0.0063% | $915.26 | $53.77M | 0.00% | ||
2024-06-28 | Sale | 10 percent owner | 1,441 0.0002% | $915.02 | $1.32M | 0.00% | ||
2024-06-25 | Sale | 10 percent owner | 188,100 0.0198% | $903.82 | $170.01M | -0.69% | ||
2024-06-24 | Sale | 10 percent owner | 17,229 0.0018% | $902.38 | $15.55M | +1.09% | ||
2024-06-20 | Sale | 10 percent owner | 9,671 0.0011% | $902.67 | $8.73M | +1.02% | ||
2024-06-17 | Sale | 10 percent owner | 194,978 0.021% | $885.91 | $172.73M | +0.74% | ||
2024-06-14 | Sale | 10 percent owner | 15,022 0.0016% | $882.47 | $13.26M | +1.48% | ||
2024-06-10 | Sale | 10 percent owner | 75,510 0.0079% | $860.78 | $65M | +2.90% | ||
2024-06-07 | Sale | 10 percent owner | 139,490 0.0147% | $852.29 | $118.89M | +4.55% | ||
2024-06-06 | Sale | 10 percent owner | 179,617 0.0189% | $837.82 | $150.49M | +5.96% | ||
2024-06-05 | Sale | 10 percent owner | 20,383 0.0022% | $836.32 | $17.05M | +6.59% |
LILLY ENDOWMENT INC | 10 percent owner | 96891978 10.2065% | $795.35 | 0 | 434 | |
Norton Johna | EVP, Global Quality | 25428 0.0027% | $795.35 | 0 | 4 | |
Zakrowski Donald A | SVP, Finance, & CAO | 5480 0.0006% | $795.35 | 0 | 27 | |
TAUREL SIDNEY | Chairman | 635952 0.067% | $795.35 | 0 | 1 | |
LECHLEITER JOHN C | former director | 160068 0.0169% | $795.35 | 1 | 2 | <0.0001% |
Ricks David A | President & CEO | 157405 0.0166% | $795.35 | 1 | 6 | +34.48% |
Simmons Jeffrey N | SVP&Pres. Elanco Animal Health | 135458 0.0143% | $795.35 | 0 | 6 | |
Conterno Enrique A | SVP&Pres, LillyDiab & LillyUSA | 132962 0.014% | $795.35 | 0 | 18 | |
Harrington Michael J | Senior VP and General Counsel | 110300 0.0116% | $795.35 | 0 | 2 | |
Fry Stephen F | SVP, HR & Diversity | 100211 0.0106% | $795.35 | 0 | 8 | |
GOLDEN CHARLES E | Exec. Vice President and CFO | 93284 0.0098% | $795.35 | 0 | 4 | |
Crowe Maria A | President, Mfg. Operations | 92484 0.0097% | $795.35 | 0 | 3 | |
SANTINI GINO | Sr.VP, Corp. Strategy & BD | 81045 0.0085% | $795.35 | 0 | 2 | |
Lundberg Jan M | EVP,Science&Tech and Pres. LRL | 77420 0.0082% | $795.35 | 0 | 5 | |
TALLARIGO LORENZO | President, Internat'l Opers. | 76105 0.008% | $795.35 | 0 | 7 | |
Skovronsky Daniel | SVP, CSO, and Pres. LRL | 75818 0.008% | $795.35 | 2 | 0 | +34.08% |
TAI JACKSON P | 62857 0.0066% | $795.35 | 12 | 0 | +14.08% | |
White Anne E. | EVP & Pres, Lilly Neuroscience | 57926 0.0061% | $795.35 | 1 | 2 | +34.48% |
Walsh Fionnuala M | SVP, Global Quality | 55618 0.0059% | $795.35 | 0 | 3 | |
Carmine Bryce D. | EVP and Pres, Lilly Bio-Meds | 51266 0.0054% | $795.35 | 0 | 16 | |
PAUL STEVEN M | EVP, Science and Technology | 50300 0.0053% | $795.35 | 0 | 8 | |
Mahony Susan | SVP & Pres., Lilly Oncology | 40685 0.0043% | $795.35 | 0 | 11 | |
Rice Derica W | EVP-Global Services and CFO | 38292 0.004% | $795.35 | 0 | 13 | |
ARMITAGE ROBERT A | Sr. VP and General Counsel | 37162 0.0039% | $795.35 | 0 | 1 | |
Jonsson Patrik | EVP&Pres, LLY Imm, LLY USA&CCO | 36941 0.0039% | $795.35 | 0 | 3 | |
Tapiero Jacques | SVP&Pres., Emerging Markets | 33302 0.0035% | $795.35 | 0 | 10 | |
Smiley Joshua L | SVP and CFO | 31524 0.0033% | $795.35 | 3 | 1 | +19.97% |
Barnes Melissa S | Chief Eth/Cmpl Ofcr & SVP, ERM | 23580 0.0025% | $795.35 | 0 | 5 | |
HORN KAREN N | director | 23054 0.0024% | $795.35 | 0 | 1 | |
Nobles Anne | Chief Eth/Cmpl Ofcr & SVP, ERM | 20937 0.0022% | $795.35 | 0 | 2 | |
Zulueta Alfonso G | SVP & President, Lilly Int'l | 18646 0.002% | $795.35 | 0 | 16 | |
Shah Aarti S. | SVP & CIO | 19087 0.002% | $795.35 | 0 | 2 | |
HANISH ARNOLD C | Chief Accounting Officer | 17747 0.0019% | $795.35 | 0 | 6 | |
Connelly Deirdre P | President, U.S. Operations | 17737 0.0019% | $795.35 | 0 | 1 | |
Runge Marschall S | director | 15436 0.0016% | $795.35 | 1 | 0 | +30.13% |
Deane Frank M | President, Mfg. Operations | 12124 0.0013% | $795.35 | 0 | 4 | |
Yuffa Ilya | SVP & President, LLY Int'l | 11624 0.0012% | $795.35 | 0 | 2 | |
O'Neill Myles | SVP & Pres., Mfg. Operations | 8469 0.0009% | $795.35 | 0 | 3 | |
Weems Alonzo | EVP, ERM & CECO | 7760 0.0008% | $795.35 | 0 | 4 | |
HOOVER R DAVID | director | 1500 0.0002% | $795.35 | 1 | 0 | +13.86% |
Canute Scott A | President, Mfg. Operations | 753 0.0001% | $795.35 | 0 | 1 | |
Shaw Christi | SVP and Pres., Lilly Bio-Meds | 500 0.0001% | $795.35 | 0 | 2 | |
Bald Eagle Acquisition Corp | 10 percent owner | 100 0% | $795.35 | 1 | 0 | +7.66% |
Tyto Acquisition Corp | 10 percent owner | 100 0% | $795.35 | 1 | 0 | +13.98% |
Kearny Acquisition Corp | director | 100 0% | $795.35 | 1 | 0 | +18.64% |
Lilly Endowment | $76.94B | 10.41 | 98.9M | -0.87% | -$676.83M | 100 | |
The Vanguard Group | $56.59B | 7.65 | 72.75M | +1.58% | +$882.06M | 1.04 | |
BlackRock | $50.78B | 6.87 | 65.27M | +1.41% | +$706.35M | 1.11 | |
PNC Financial Services | $40.02B | 5.41 | 51.44M | -0.53% | -$211.04M | 27.99 | |
State Street | $26.65B | 3.61 | 34.26M | +1.4% | +$366.61M | 1.09 | |
Fidelity Investments | $26.51B | 3.59 | 34.08M | +3.77% | +$962.38M | 1.77 | |
Capital World Investors | $19.09B | 2.58 | 24.54M | -8.96% | -$1.88B | 3.17 | |
PRIMECAP Management Co | $16.53B | 2.24 | 21.25M | -4.26% | -$736.22M | 12.14 | |
T. Rowe Price | $16.04B | 2.17 | 20.61M | -5.56% | -$944.07M | 1.97 | |
JPMorgan Chase | $14.94B | 2.02 | 19.2M | -0.37% | -$55.02M | 1.33 | |
Geode Capital Management | $12.86B | 1.74 | 16.58M | +3.88% | +$480.73M | 1.09 | |
Morgan Stanley | $10.17B | 1.38 | 13.07M | +3.23% | +$318.07M | 0.75 | |
State Farm | $9.84B | 1.33 | 12.65M | -22.68% | -$2.89B | 8.86 | |
Wellington Management Company | $8.57B | 1.16 | 11.02M | -6.48% | -$594.13M | 1.45 | |
Bank of America | $8.22B | 1.11 | 10.57M | +6.94% | +$533.84M | 0.79 | |
Northern Trust | $6.87B | 0.93 | 8.84M | -3.25% | -$230.97M | 1.12 | |
Capital Research Global Investors | $6.25B | 0.85 | 8.03M | +5.99% | +$353.15M | 1.42 | |
JENNISON ASSOCIATES LLC | $5.81B | 0.79 | 7.47M | -1.73% | -$102M | 3.89 | |
Legal & General | $5.53B | 0.75 | 7.11M | -0.31% | -$16.98M | 1.28 | |
Capital International Investors | $5.42B | 0.73 | 6.97M | +5.06% | +$261.05M | 1.1 | |
BNY Mellon | $5.27B | 0.71 | 6.77M | -8.34% | -$479.42M | 0.99 | |
Nuveen | $4.11B | 0.56 | 5.29M | -1.47% | -$61.24M | 1.18 | |
AllianceBernstein | $3.72B | 0.5 | 4.79M | -5.43% | -$213.73M | 1.31 | |
Fisher Asset Management Llc | $3.65B | 0.49 | 4.69M | +3.32% | +$117.29M | 1.71 | |
Charles Schwab | $3.64B | 0.49 | 4.67M | +2.49% | +$88.46M | 0.79 | |
Ubs Asset Management Americas Inc | $3.59B | 0.49 | 4.62M | +2.7% | +$94.54M | 1.27 | |
Goldman Sachs | $3.52B | 0.48 | 4.52M | -3.43% | -$124.76M | 0.65 | |
Amundi | $3.04B | 0.43 | 4.07M | +8.49% | +$237.59M | 1.27 | |
Franklin Templeton Investments | $3.02B | 0.41 | 3.88M | +66.95% | +$1.21B | 0.9 | |
GQG Partners | $2.99B | 0.41 | 3.85M | +20.25% | +$504.19M | 4.82 | |
Janus Henderson | $2.78B | 0.38 | 3.58M | +7.32% | +$189.6M | 1.4 | |
Dimensional Fund Advisors | $2.65B | 0.36 | 3.41M | +0.4% | +$10.57M | 0.68 | |
Invesco | $2.45B | 0.33 | 3.15M | +2.68% | +$63.91M | 0.51 | |
Deutsche Bank | $2.44B | 0.33 | 3.14M | +11.3% | +$247.95M | 1.1 | |
Massachusetts Financial Services Co Ma | $2.42B | 0.33 | 3.11M | -3.12% | -$78.01M | 0.72 | |
Dz Bank Ag Deutsche Zentral Genossenschafts Bank Frankfurt Am Main | $2.4B | 0.33 | 3.09M | +11.37% | +$245.4M | 2.59 | |
Ameriprise Financial | $2.34B | 0.32 | 3.01M | -4.63% | -$113.54M | 0.65 | |
Wells Fargo | $2.27B | 0.31 | 2.92M | -4.17% | -$98.9M | 0.6 | |
UBS | $2.09B | 0.28 | 2.69M | +5.71% | +$113M | 0.62 | |
Swiss National Bank | $1.88B | 0.25 | 2.42M | -4.23% | -$83.09M | 1.23 | |
Royal Bank of Canada | $1.84B | 0.25 | 2.37M | +0.65% | +$11.81M | 0.44 | |
Edgewood Management | $1.81B | 0.25 | 2.32M | +3.12% | +$54.76M | 4.86 | |
HSBC | $1.7B | 0.23 | 2.19M | +25% | +$339.71M | 1.21 | |
U.S. Bancorp | $1.65B | 0.22 | 2.13M | -1.58% | -$26.64M | 2.3 | |
Schroder Investment Management Group | $1.65B | 0.22 | 2.12M | -3.06% | -$51.95M | 1.95 | |
Barclays | $1.64B | 0.22 | 2.11M | -18.69% | -$376.84M | 0.74 | |
Sumitomo Mitsui Trust Holdings | $1.62B | 0.22 | 2.08M | -0.88% | -$14.32M | 1.09 | |
CalPERS | $1.61B | 0.22 | 2.07M | -3.97% | -$66.78M | 1.13 | |
American Century Investments | $1.53B | 0.21 | 1.97M | -0.36% | -$5.51M | 0.94 | |
Bank of Montreal | $1.41B | 0.19 | 1.81M | -5.39% | -$80.54M | 0.44 |